OrthoPediatrics Corp. (KIDS) Stock

OrthoPediatrics Corp. (KIDS) is a Healthcare stock trading at $26.26 (as of 2026-08-20), with a market capitalization of $685.64M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

OrthoPediatrics Corp. designs, develops, and markets orthopedic implants and devices for treating pediatric patients with conditions such as trauma and deformity correction, scoliosis, and sports medicine. The company’s offerings are used by pediatric orthopedic surgeons and caregivers in the United States and internationally.

Understand OrthoPediatrics Corp.: how it makes money

OrthoPediatrics makes anatomically appropriate orthopedic implants and devices for children, sold through product sales and related procedures, with revenue led by domestic and also supported by international sales and Seven D capital sales.

The profit engine is procedure-driven device and implant demand (tracked via children treated and set deployments), where most revenue comes from domestic sales, and near-term profitability depends on whether operating expenses scale down enough to convert that gross margin into positive operating income.

Revenue by segment (latest quarter)
Domestic$0.1B
International$0.0B
SevenDCap$0.0B

Business quality (Weak): Strong gross margin but an operating loss, with revenue concentrated in the domestic market and limited contribution from sports medicine and other lines in the latest quarter.

Bull case

  • High gross margin: Gross margin was 73.1% in the latest period.
  • Meaningful domestic scale: Domestic Revenue was 0.05B versus International Revenue of 0.01B.
  • Demand signals across core procedure areas: Trauma and Deformity Revenue was 0.04B and Scoliosis Revenue was 0.02B.

Bear case

  • Operating loss: Operating margin was -14.0% in the latest period, indicating operating expenses outweighed gross profit.
  • Limited contribution from some product lines: Sports Medicine and Other Revenue was 0.0B and MD Orthopedics and Pega Medical Combined Revenue was 0.0B in the provided segment candidates.
  • Domestic concentration risk: Domestic Revenue (0.05B) materially exceeds International Revenue (0.01B), which can increase sensitivity to domestic demand or reimbursement conditions.
Valuation — source: SEC EDGAR (first-party)
Price$26.26
Market Cap$685.64M
EV / EBITDA93.5
Price / Book2.00
Price / Sales2.74
FCF Yield-6.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$236.35M
Net Margin-16.8%
Revenue Growth (YoY)15.4%
EPS Growth (YoY)3.0%
FCF Growth (YoY)-61.4%
Financial Health — source: SEC EDGAR
Altman Z-Score2.41 (grey)
Piotroski F-Score4/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBROWN ADVISORY INC ($24.09M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEODavid R. Bailey
Employees562
CountryUS
IPO Date2017-10-13

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Beta Bionics, Inc. (BBNX)
  • SS Innovations International, Inc. (SSII)
  • AngioDynamics, Inc. (ANGO)
  • MiMedx Group, Inc. (MDXG)
  • Delcath Systems, Inc. (DCTH)
  • Cerus Corporation (CERS)
  • Tactile Systems Technology, Inc. (TCMD)
  • NeuroPace, Inc. (NPCE)
KIDS earnings history · KIDS institutional & insider holders · KIDS KPIs & operating metrics · KIDS financials · KIDS investor presentations & press releases · KIDS SEC filings · KIDS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.